Fire Capital Management LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 38,367 shares of the biopharmaceutical company's stock, valued at approximately $1,018,000.
A number of other hedge funds also recently added to or reduced their stakes in PFE. Norges Bank acquired a new stake in Pfizer during the 4th quarter worth approximately $2,328,986,000. Charles Schwab Investment Management Inc. lifted its holdings in Pfizer by 19.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock worth $4,124,330,000 after buying an additional 25,315,159 shares in the last quarter. Starboard Value LP acquired a new stake in Pfizer during the 4th quarter worth approximately $407,730,000. Raymond James Financial Inc. acquired a new stake in Pfizer during the 4th quarter worth approximately $274,694,000. Finally, Massachusetts Financial Services Co. MA lifted its holdings in Pfizer by 7.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock worth $2,029,604,000 after buying an additional 5,350,381 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.
Pfizer Stock Performance
Shares of NYSE:PFE traded up $0.01 during midday trading on Friday, hitting $23.46. The stock had a trading volume of 56,576,195 shares, compared to its average volume of 41,090,161. The company has a market capitalization of $133.38 billion, a PE ratio of 16.64, a P/E/G ratio of 0.64 and a beta of 0.58. The stock has a 50 day moving average price of $23.12 and a two-hundred day moving average price of $25.05. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54.
Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business's quarterly revenue was down 7.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.82 earnings per share. As a group, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Pfizer Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.33%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's dividend payout ratio (DPR) is 124.64%.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on the stock. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Citigroup restated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Cantor Fitzgerald began coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price on the stock. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Finally, UBS Group increased their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $29.17.
Read Our Latest Research Report on PFE
About Pfizer
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Stories
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
